Publications by authors named "Douglas Jabs"
Purpose: Evaluation of longer-term effectiveness of three intravitreal therapies (methotrexate, ranibizumab, or dexamethasone implant) for participants enrolled in the randomized comparative effectiveness trial the Macular Edema Ranibizumab versus Intravitreal anti-inflammatory Therapy (MERIT) Trial followed for24 weeks.
Design: Multicenter randomized controlled clinical trial with masked evaluation of retinal thickness and visual acuity.
Participants: Patients with persistent or recurrent uveitic macular edema.
Vitamin D Supplementation and Remission from Chronic Anterior Uveitis.
Ocul Immunol Inflamm
November 2024
Purpose: Chronic anterior uveitis (CAU) often requires suppressive therapy, which has potential side effects including cataract, ocular hypertension, and increased risk of infection. No remittive therapy is currently available; however, several studies have demonstrated an association between low 25-hydroxy Vitamin D (25OHD) levels and either uveitis incidence or uveitis disease activity. This study investigates the potential of Vitamin D supplementation as a remittive treatment for CAU.
View Article and Find Full Text PDFArticle Synopsis
- - The survey, developed by the International Uveitis Study Group, aimed to assess how uveitis and retina specialists use current terminology and multimodal imaging (MMI) for diagnosing white dot syndromes (WDS).
- - Out of 432 initial respondents, 263 completed the survey, revealing that most participants specialize in uveitis and utilize MMI, with nearly 90% using it for WDS diagnosis but showing varied usage of the term WDS.
- - The findings suggest a strong consensus among specialists for redefining WDS based on anatomical location rather than the current clinical term, emphasizing MMI's role in enhancing diagnostic precision.
Purpose: To evaluate the incidence, remission, and relapse of post-surgical cystoid macular edema (PCME) following cataract surgery in inflammatory eye disease.
Methods: A total of 1859 eyes that had no visually significant macular edema prior to cataract surgery while under tertiary uveitis management were included. Standardized retrospective chart review was used to gather clinical data.
Article Synopsis
- A study evaluated the incidence of significant posterior capsule opacification (PCO) and YAG laser capsulotomy among uveitic eyes after cataract surgery, revealing that about 16% of eyes experienced PCO with reduced visual acuity within a year.* -
- Analysis of 1,855 uveitic eyes found that younger patients, those with poorer preoperative vision, and postoperative inflammation were more likely to develop PCO, while younger age and female sex were risk factors for needing YAG laser capsulotomy.* -
- The findings indicate that PCO is common in uveitic patients post-surgery, with 22% of eyes undergoing YAG laser treatment in the same timeframe, emphasizing the need for
Introduction: Patients with the acquired immunodeficiency syndrome (AIDS) have an increased prevalence and incidence of intermediate-stage age-related macular degeneration (AMD). Several elevated plasma inflammatory biomarkers are associated with increased incidence of intermediate-stage AMD in this population. We evaluated the association between AMD risk alleles and plasma inflammatory biomarker levels in persons with AIDS.
View Article and Find Full Text PDFBACKGROUNDCOVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined.METHODSThis secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double-blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup.
View Article and Find Full Text PDFPurpose: To evaluate associations of plasma levels of inflammatory biomarkers with age-related macular degeneration (AMD) and cataract in persons with AIDS.
Design: Nested case-control study (analysis 1) and nested cohort study (analysis 2).
Participants: Analysis 1: persons with AIDS and incident intermediate-stage AMD (n = 26) and controls without AMD matched for age, race/ethnicity, and gender (n = 49) from The Longitudinal Study of Ocular Complications of AIDS.
Article Synopsis
- The study aimed to analyze the relationship between immunosuppression and overall as well as cancer-specific mortality in patients with noninfectious ocular inflammatory disease.
- Researchers examined data from over 15,000 patients over a median of 10 years and found there were 1970 deaths, with 435 attributed to cancer.
- The results indicated that patients on various immunosuppressants experienced similar mortality rates compared to the general U.S. population, suggesting that these treatments did not significantly increase overall or cancer mortality risk.
Aims: To present current practice patterns in the diagnosis and management of Cytomegalovirus anterior uveitis (CMV AU) by uveitis experts worldwide.
Methods: A two-round modified Delphi survey with masking of the study team was performed. Based on experience and expertise, 100 international uveitis specialists from 21 countries were invited to participate in the survey.
Article Synopsis
- The study aimed to evaluate and create consensus guidelines among global uveitis specialists regarding the management of herpes simplex virus (HSV) and varicella-zoster virus (VZV) associated anterior uveitis (AU).
- An online Delphi survey gathered responses from 76 uveitis experts across 21 countries, with findings leading to the establishment of treatment guidelines via the TITAN working group.
- Key conclusions highlighted specific diagnostic signs for HSV and VZV AU, preferred use of valacyclovir for treatment, and a variety of opinions on treatment duration and managing recurrences.
Purpose: To estimate the incidence/risk factors for cataract in noninfectious anterior uveitis.
Design: Retrospective multicenter cohort study (6 US tertiary uveitis sites, 1978-2010).
Methods: Data were harvested by trained expert reviewers, using protocol-driven review of experts' charts.
Purpose: To evaluate the rate of, risk factors for, and outcomes of cataract surgery in patients with intermediate, posterior, and panuveitides treated with systemic corticosteroids and immunosuppression.
Design: Cohort study of participants from a randomized clinical trial.
Methods: A multicenter clinical trial with extended follow-up comprised the study setting.
Purpose: To evaluate the effectiveness of 3 different intravitreal treatments for persistent or recurrent uveitic macular edema (ME): dexamethasone implant, methotrexate, and ranibizumab.
Design: Single-masked, randomized controlled clinical trial.
Participants: Patients with minimally active or inactive uveitis and persistent or recurrent uveitic ME in one or both eyes.
Purpose: To evaluate the effectiveness of tacrolimus in patients with noninfectious intermediate, posterior, or panuveitis needing a two-immunosuppressive-agent regimen.
Methods: Design: Retrospective cohort study. Setting: Two tertiary-care uveitis practices at academic medical centers.
Background: The COVID-19 convalescent plasma (CCP) viral specific antibody levels that translate into recipient post-transfusion antibody levels sufficient to prevent disease progression is not defined.
Methods: This secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup.
Purpose: To evaluate the long-term visual acuity (VA) outcome of cataract surgery in inflammatory eye disease.
Setting: Tertiary care academic centres.
Design: Multicentre retrospective cohort study.
The uveitides are a collection of over 30 diseases characterised by intraocular inflammation. Previous work demonstrated that the agreement among uveitis experts on diagnosis was modest at best with some pairs of experts having chance alone agreement on selected diseases. The Standardisation of Uveitis Nomenclature (SUN) is a17-year collaboration among experts in uveitis, ocular image grading, informatics, and machine learning to improve clinical and translational uveitis research.
View Article and Find Full Text PDFBackground: The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.
Methods: This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma.
Purpose: To estimate the incidence of scleritis in Lyme disease and report clinical features.
Design: Incidence rate estimate and case series.
Methods: Data were collected from an electronic medical record on patients with scleritis presenting to the Wilmer Eye Institute between January 1, 2012 and December 31, 2020.
Article Synopsis
- Uveitides are over 30 diseases causing inflammation in the eye, often treated with oral corticosteroids and immunosuppressants, complicating clinical trials due to their rarity and diverse characteristics.
- Many trials have faced challenges with efficacy measures, leading to unclear results and difficulties in recruitment due to the need for a specific outcome measure for each disease.
- A promising approach involves using a single outcome focusing on successful corticosteroid sparing (inactive uveitis with low prednisone) to streamline assessment, which is currently being tested in the ADVISE Trial.
Background: Polyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain.
Methods: In this multicenter, double-blind, randomized, controlled trial, we evaluated the efficacy and safety of Covid-19 convalescent plasma, as compared with control plasma, in symptomatic adults (≥18 years of age) who had tested positive for severe acute respiratory syndrome coronavirus 2, regardless of their risk factors for disease progression or vaccination status.
Purpose: To describe treatment-related outcomes among patients with birdshot chorioretinitis (BSCR).
Design: Retrospective cohort study.
Participants: Patients diagnosed with BSCR at 2 tertiary care academic medical centers.
Background: The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain.
Methods: This multicenter, double-blind randomized controlled trial compared the efficacy and safety of SARS-CoV-2 high titer convalescent plasma to placebo control plasma in symptomatic adults ≥18 years positive for SARS-CoV-2 regardless of risk factors for disease progression or vaccine status. Participants with symptom onset within 8 days were enrolled, then transfused within the subsequent day.